Figure 3
Efficacy and safety outcomes in fragile patients and subgroups. a. Primary efficacy. b. Major bleeding. CI, Confidence interval; HR, Hazard ratio; VKA, Vitamin K antagonist.
Figure 3 | Thrombosis Journal
Efficacy and safety outcomes in fragile patients and subgroups. a. Primary efficacy. b. Major bleeding. CI, Confidence interval; HR, Hazard ratio; VKA, Vitamin K antagonist.